Pharmacokinetics and safety of fibrinogen concentrate

M. J. Manco-Johnson, D. Dimichele, G. Castaman, S. Fremann, S. Knaub, U. Kalina, F. Peyvandi, G. Piseddu, P. Mannucci

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Background: Although fibrinogen concentrate has been available for the treatment of congenital fibrinogen deficiency for years, knowledge of its pharmacokinetics comes from only two small studies. Objectives: To assess the pharmacokinetic (PK) profile, clot integrity and safety of fibrinogen concentrate (human) (FCH) in patients with afibrinogenemia. Patients and methods: A multinational, prospective, open-label, uncontrolled study of patients with afibrinogenemia ≥6 years of age was conducted in the USA and Italy. Plasma was collected before and after infusion for PK analyses and evaluation by rotational thromboelastometry of maximum clot firmness (MCF) to assess clot integrity. Safety was assessed on the basis of adverse events and laboratory parameters. Results: After a single dose of 70mgkg -1 body weight (b.w.) FCH in 14 patients, median incremental in vivo recovery was a 1.7mgdL -1 increase per mgkg -1 b.w., and median levels were 1.3gL -1 for fibrinogen activity and antigen 1h after infusion. Median half-life (t 1/2) was 77.1h for fibrinogen activity and 88.0h for antigen. Plasma recovery in children 1/2 and area under the curve were decreased, with an increased steady-state volume and clearance. MCF increased by a mean of 8.9mm from baseline to 1h after infusion of FCH (P

Original languageEnglish
Pages (from-to)2064-2069
Number of pages6
JournalJournal of Thrombosis and Haemostasis
Volume7
Issue number12
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Afibrinogenemia
Fibrinogen
Pharmacokinetics
Safety
Body Weight
Thrombelastography
Antigens
Italy
Area Under Curve
Half-Life
Therapeutics

Keywords

  • Afibrinogenemia
  • Clot integrity
  • Fibrinogen concentrate
  • Maximum clot firmness
  • Pharmacokinetic
  • Safety

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Manco-Johnson, M. J., Dimichele, D., Castaman, G., Fremann, S., Knaub, S., Kalina, U., ... Mannucci, P. (2009). Pharmacokinetics and safety of fibrinogen concentrate. Journal of Thrombosis and Haemostasis, 7(12), 2064-2069. https://doi.org/10.1111/j.1538-7836.2009.03633.x

Pharmacokinetics and safety of fibrinogen concentrate. / Manco-Johnson, M. J.; Dimichele, D.; Castaman, G.; Fremann, S.; Knaub, S.; Kalina, U.; Peyvandi, F.; Piseddu, G.; Mannucci, P.

In: Journal of Thrombosis and Haemostasis, Vol. 7, No. 12, 12.2009, p. 2064-2069.

Research output: Contribution to journalArticle

Manco-Johnson, MJ, Dimichele, D, Castaman, G, Fremann, S, Knaub, S, Kalina, U, Peyvandi, F, Piseddu, G & Mannucci, P 2009, 'Pharmacokinetics and safety of fibrinogen concentrate', Journal of Thrombosis and Haemostasis, vol. 7, no. 12, pp. 2064-2069. https://doi.org/10.1111/j.1538-7836.2009.03633.x
Manco-Johnson MJ, Dimichele D, Castaman G, Fremann S, Knaub S, Kalina U et al. Pharmacokinetics and safety of fibrinogen concentrate. Journal of Thrombosis and Haemostasis. 2009 Dec;7(12):2064-2069. https://doi.org/10.1111/j.1538-7836.2009.03633.x
Manco-Johnson, M. J. ; Dimichele, D. ; Castaman, G. ; Fremann, S. ; Knaub, S. ; Kalina, U. ; Peyvandi, F. ; Piseddu, G. ; Mannucci, P. / Pharmacokinetics and safety of fibrinogen concentrate. In: Journal of Thrombosis and Haemostasis. 2009 ; Vol. 7, No. 12. pp. 2064-2069.
@article{92be604627104d45936621ad99b6c0d9,
title = "Pharmacokinetics and safety of fibrinogen concentrate",
abstract = "Background: Although fibrinogen concentrate has been available for the treatment of congenital fibrinogen deficiency for years, knowledge of its pharmacokinetics comes from only two small studies. Objectives: To assess the pharmacokinetic (PK) profile, clot integrity and safety of fibrinogen concentrate (human) (FCH) in patients with afibrinogenemia. Patients and methods: A multinational, prospective, open-label, uncontrolled study of patients with afibrinogenemia ≥6 years of age was conducted in the USA and Italy. Plasma was collected before and after infusion for PK analyses and evaluation by rotational thromboelastometry of maximum clot firmness (MCF) to assess clot integrity. Safety was assessed on the basis of adverse events and laboratory parameters. Results: After a single dose of 70mgkg -1 body weight (b.w.) FCH in 14 patients, median incremental in vivo recovery was a 1.7mgdL -1 increase per mgkg -1 b.w., and median levels were 1.3gL -1 for fibrinogen activity and antigen 1h after infusion. Median half-life (t 1/2) was 77.1h for fibrinogen activity and 88.0h for antigen. Plasma recovery in children 1/2 and area under the curve were decreased, with an increased steady-state volume and clearance. MCF increased by a mean of 8.9mm from baseline to 1h after infusion of FCH (P",
keywords = "Afibrinogenemia, Clot integrity, Fibrinogen concentrate, Maximum clot firmness, Pharmacokinetic, Safety",
author = "Manco-Johnson, {M. J.} and D. Dimichele and G. Castaman and S. Fremann and S. Knaub and U. Kalina and F. Peyvandi and G. Piseddu and P. Mannucci",
year = "2009",
month = "12",
doi = "10.1111/j.1538-7836.2009.03633.x",
language = "English",
volume = "7",
pages = "2064--2069",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Pharmacokinetics and safety of fibrinogen concentrate

AU - Manco-Johnson, M. J.

AU - Dimichele, D.

AU - Castaman, G.

AU - Fremann, S.

AU - Knaub, S.

AU - Kalina, U.

AU - Peyvandi, F.

AU - Piseddu, G.

AU - Mannucci, P.

PY - 2009/12

Y1 - 2009/12

N2 - Background: Although fibrinogen concentrate has been available for the treatment of congenital fibrinogen deficiency for years, knowledge of its pharmacokinetics comes from only two small studies. Objectives: To assess the pharmacokinetic (PK) profile, clot integrity and safety of fibrinogen concentrate (human) (FCH) in patients with afibrinogenemia. Patients and methods: A multinational, prospective, open-label, uncontrolled study of patients with afibrinogenemia ≥6 years of age was conducted in the USA and Italy. Plasma was collected before and after infusion for PK analyses and evaluation by rotational thromboelastometry of maximum clot firmness (MCF) to assess clot integrity. Safety was assessed on the basis of adverse events and laboratory parameters. Results: After a single dose of 70mgkg -1 body weight (b.w.) FCH in 14 patients, median incremental in vivo recovery was a 1.7mgdL -1 increase per mgkg -1 b.w., and median levels were 1.3gL -1 for fibrinogen activity and antigen 1h after infusion. Median half-life (t 1/2) was 77.1h for fibrinogen activity and 88.0h for antigen. Plasma recovery in children 1/2 and area under the curve were decreased, with an increased steady-state volume and clearance. MCF increased by a mean of 8.9mm from baseline to 1h after infusion of FCH (P

AB - Background: Although fibrinogen concentrate has been available for the treatment of congenital fibrinogen deficiency for years, knowledge of its pharmacokinetics comes from only two small studies. Objectives: To assess the pharmacokinetic (PK) profile, clot integrity and safety of fibrinogen concentrate (human) (FCH) in patients with afibrinogenemia. Patients and methods: A multinational, prospective, open-label, uncontrolled study of patients with afibrinogenemia ≥6 years of age was conducted in the USA and Italy. Plasma was collected before and after infusion for PK analyses and evaluation by rotational thromboelastometry of maximum clot firmness (MCF) to assess clot integrity. Safety was assessed on the basis of adverse events and laboratory parameters. Results: After a single dose of 70mgkg -1 body weight (b.w.) FCH in 14 patients, median incremental in vivo recovery was a 1.7mgdL -1 increase per mgkg -1 b.w., and median levels were 1.3gL -1 for fibrinogen activity and antigen 1h after infusion. Median half-life (t 1/2) was 77.1h for fibrinogen activity and 88.0h for antigen. Plasma recovery in children 1/2 and area under the curve were decreased, with an increased steady-state volume and clearance. MCF increased by a mean of 8.9mm from baseline to 1h after infusion of FCH (P

KW - Afibrinogenemia

KW - Clot integrity

KW - Fibrinogen concentrate

KW - Maximum clot firmness

KW - Pharmacokinetic

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=77449130904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449130904&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2009.03633.x

DO - 10.1111/j.1538-7836.2009.03633.x

M3 - Article

C2 - 19804533

AN - SCOPUS:77449130904

VL - 7

SP - 2064

EP - 2069

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 12

ER -